Abnormal kinetics of erythrocyte sodium lithium countertransport in renal transplant recipients

Transplantation Proceedings
K VareesangthipL Ong-Aj-Yooth

Abstract

Cardiovascular disease is now the most common cause of death in renal transplantation. Cyclosporine (CsA)-associated hypertension might be a major cause of cardiovascular risk factors. There is evidence suggesting that one mechanism of CsA toxicity might be mediated through alteration of membrane lipid peroxidation, which can activate cellular pathways. Erythrocyte sodium lithium countertransport (Na/Li CT) is a sensitive membrane protein that is abnormal in several hypertensive-related diseases. We have studied the kinetics of erythrocyte Na/Li CT in 38 renal transplant recipients. Group 1 (15 patients) received CsA, azathioprine, and prednisolone (C+A+P), Group 2 (15 patients) CsA and prednisolone (C+P), and Group 3 (8 patients) azathioprine and prednisolone (A+P). Compared with the normal subjects, the Michaelis constant for extracellular sodium (Km) of erythrocyte Na/Li CT was lower among the CsA-based regimen groups (C+A+P and C+P), but not the A+P group. The maximum velocity (Vmax)/Km ratio was also higher among the C+A+P and C+P groups than the A+P group. These abnormalities of Na/Li CT kinetics might be due to abnormalities of cell membrane functions, caused by immunosuppressive drugs, particularly CsA. Further studies ...Continue Reading

References

Jun 1, 1992·Journal of the American Society of Nephrology : JASN·J D PirschF O Belzer
Jan 1, 1992·European Journal of Clinical Investigation·P A RutherfordR Wilkinson
Apr 1, 1991·Journal of Leukocyte Biology·C D Niebylski, H R Petty
Mar 1, 1986·The Journal of General Physiology·P A Hannaert, R P Garay
Dec 21, 1989·The New England Journal of Medicine·B D Kahan
Jun 1, 1988·The American Journal of Medicine·B L Kasiske
Jan 21, 1988·The New England Journal of Medicine·A S KrolewskiL I Rand
Apr 3, 1980·The New England Journal of Medicine·M CanessaD C Tosteson
May 4, 1995·Biochimica Et Biophysica Acta·T H ThomasR Wilkinson
Sep 15, 1993·JAMA : the Journal of the American Medical Association·F K PortK Jiang
Jun 1, 1996·Journal of Hypertension·T C Hardman, A F Lant
Dec 1, 1995·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·K VareesangthipR Wilkinson
Aug 8, 1997·Clinica Chimica Acta; International Journal of Clinical Chemistry·L T McGrathJ H Brown
Apr 9, 1998·Journal of Hypertension·I C WestT H Thomas
Dec 23, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·R SchindlerU Frei
Mar 7, 2000·Journal of the American Society of Nephrology : JASN·John R Silkensen
Apr 1, 2000·Biochimica Et Biophysica Acta·R R ThakkarW D Ehringer
Apr 29, 2000·Current Opinion in Urology·A R Rosenkranz, G Mayer

❮ Previous
Next ❯

Citations

May 6, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Angela Q MaldonadoJennifer Trofe-Clark

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.